Vaxcyte (NASDAQ:PCVX – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Valuation and Earnings
This table compares Vaxcyte and Aligos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vaxcyte | N/A | N/A | -$402.27 million | ($4.28) | -27.28 |
| Aligos Therapeutics | $7.97 million | 141.08 | -$87.68 million | ($1.28) | -11.24 |
Aligos Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxcyte | 0 | 0 | 7 | 0 | 3.00 |
| Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Vaxcyte currently has a consensus target price of $147.50, indicating a potential upside of 26.34%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 421.20%. Given Aligos Therapeutics’ higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Vaxcyte.
Insider and Institutional Ownership
96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 16.5% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Vaxcyte has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Profitability
This table compares Vaxcyte and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxcyte | N/A | -30.07% | -28.08% |
| Aligos Therapeutics | -1,100.48% | -110.59% | -63.90% |
Summary
Aligos Therapeutics beats Vaxcyte on 7 of the 12 factors compared between the two stocks.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
